Sensitive deep-sequencing-based HIV-1 genotyping assay to simultaneously determine susceptibility to protease, reverse transcriptase, integrase, and maturation inhibitors, as well as HIV-1 coreceptor tropism

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 4, 2014, Pages 2167-2185

  Gibson, Richard M ^a   Meyer, Ashley M ^a   Winner, Dane ^a   Archer, John ^b   Feyertag, Felix ^b   Ruiz Mateos, Ezequiel ^c   Leal, Manuel ^c   Robertson, David L ^b   Schmotzer, Christine L ^a   Quiñones Mateu, Miguel E ^a,d  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c Instituto de Biomedicina de Sevilla   (Spain)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTEGRASE; INTEGRASE INHIBITOR; PROTEINASE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

AMINO ACID SUBSTITUTION; ARTICLE; CODON; DRUG SENSITIVITY; GENE MUTATION; GENETIC DISTANCE; GENETIC VARIABILITY; GENOTYPING TECHNIQUE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; INDEL MUTATION; LIMIT OF DETECTION; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA VIRUS; VIRAL TROPISM; VIRUS LOAD;

ANTI-HIV AGENTS; GENOTYPE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HIV-1; HUMANS; INTEGRASES; POLYMERASE CHAIN REACTION; RECEPTORS, HIV; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA-DIRECTED DNA POLYMERASE;

EID: 84896944940     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02710-13     Document Type: Article

References (129)

1. WHO. 2013. Global update on HIV treatment 2013: results, impact, and opportunities. World Health Organizzation, Geneva, Switzerland. http://apps.who.int/iris/bitstream/10665/85327/1/WHO-HIV-2013.9-eng.pdf.
2. Paredes R, Clotet B. 2010. Clinical management of HIV-1 resistance. Antiviral Res. 85:245-265. http://dx.doi.org/10.1016/j.antiviral.2009.09.015.
3. Zolopa AR. 2010. The evolution of HIV treatment guidelines: current state-of-the-art of ART. Antiviral Res. 85:241-244. http://dx.doi.org/10.1016/j. antiviral.2009.10.018.
4. Deeks SG. 2003. Treatment of antiretroviral-drug-resistant HIV-1 infection. Lancet 362:2002-2011. http://dx.doi.org/10.1016/S0140-6736(03)15022- 2. (Pubitemid 37548427)
5. Tang JW, Pillay D. 2004. Transmission of HIV-1 drug resistance. J. Clin. Virol. 30:1-10. http://dx.doi.org/10.1016/j.jcv.2003.12.002. (Pubitemid 38457061)
6. Johnson VA, Calvez V, Günthard HF, Paredes R, Pillay D, Shafer R, Wensing AM, Richman DD. 2011. 2011 update of the drug resistance mutations in HIV-1. Top. Antivir. Med. 19:156-164.
7. Weber J, Piontkivska H, Quiñones-Mateu ME. 2006. HIV type 1 tropism and inhibitors of viral entry: clinical implications. AIDS Rev. 8:60-77. (Pubitemid 44043555)
8. Rose JD, Rhea AM, Weber J, Quiñones-Mateu ME. 2009. Current tests to evaluate HIV-1 coreceptor tropism. Curr. Opin. HIV AIDS 4:136-142. http://dx.doi.org/10.1097/COH.0b013e328322f973.
9. Rhee SY, Taylor J, Wadhera G, Ben-Hur A, Brutlag DL, Shafer RW. 2006. Genotypic predictors of human immunodeficiency virus type 1 drug resistance. Proc. Natl. Acad. Sci. U. S. A. 103:17355-17360. http://dx.doi.org/10.1073/pnas. 0607274103. (Pubitemid 44788973)
10. Paar C, Palmetshofer C, Flieger K, Geit M, Kaiser R, Stekel H, Berg J. 2008. Genotypic antiretroviral resistance testing for human immunodeficiency virus type 1 integrase inhibitors by use of the TruGene sequencing system. J. Clin. Microbiol. 46:4087-4090. http://dx.doi.org/10.1128/JCM.01246-08.
11. Hertogs K, de Béthune MP, Miller V, Ivens T, Schel P, Van Cauwenberge A, Van Den Eynde C, Van Gerwen V, Azijn H, Van Houtte M, Peeters F, Staszewski S, Conant M, Bloor S, Kemp S, Larder B, Pauwels R. 1998. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob. Agents Chemother. 42: 269-276. http://dx.doi.org/10.1093/jac/42.2.269.
12. Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, Huang W, Tian H, Smith D, Winslow GA, Capon DJ, Whitcomb JM. 2000. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 44:920-928. http://dx.doi.org/10.1128/AAC.44.4.920-928.2000. (Pubitemid 30165271)
13. Weber J, Vazquez AC, Winner D, Rose JD, Wylie D, Rhea AM, Henry K, Pappas J, Wright A, Mohamed N, Gibson R, Rodriguez B, Soriano V, King K, Arts EJ, Olivo PD, Quiñones-Mateu ME. 2011. Novel method for simultaneous quantification of phenotypic resistance to maturation, protease, reverse transcriptase, and integrase HIV inhibitors based on 3′Gag(p2/ p7/p1/p6)/PR/RT/INT-recombinant viruses: a useful tool in the multitarget era of antiretroviral therapy. Antimicrob. Agents Chemother. 55:3729-3742. http://dx.doi.org/10.1128/AAC.00396-11.
14. Vermeiren H, Van Craenenbroeck E, Alen P, Bacheler L, Picchio G, Lecocq P, Virco Clinical Response Collaborative Team. 2007. Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling. J. Virol. Methods 145:47-55. http://dx.doi.org/10.1016/j.jviromet. 2007.05.009. (Pubitemid 47247892)
15. Poveda E, Briz V, Quiñones-Mateu M, Soriano V. 2006. HIV tropism: diagnostic tools and implications for disease progression and treatment with entry inhibitors. AIDS 20:1359-1367. http://dx.doi.org/10.1097/01.aids. 0000233569.74769.69.
16. Obermeier M, Symons J, Wensing AM. 2012. HIV population genotypic tropism testing and its clinical significance. Curr. Opin. HIV AIDS 7:470-477. http://dx.doi.org/10.1097/COH.0b013e328356eaa7.
17. Raymond S, Delobel P, Izopet J. 2012. Phenotyping methods for determining HIV tropism and applications in clinical settings. Curr. Opin. HIV AIDS 7:463-469. http://dx.doi.org/10.1097/COH.0b013e328356f6d7.
18. Trouplin V, Salvatori F, Cappello F, Obry V, Brelot A, Heveker N, Alizon M, Scarlatti G, Clavel F, Mammano F. 2001. Determination of coreceptor usage of human immunodeficiency virus type 1 from patient plasma samples by using a recombinant phenotypic assay. J. Virol. 75: 251-259. http://dx.doi.org/10.1128/ JVI.75.1.251-259.2001.
19. Whitcomb JM, Huang W, Fransen S, Limoli K, Toma J, Wrin T, Chappey C, Kiss LD, Paxinos EE, Petropoulos CJ. 2007. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob. Agents Chemother. 51:566-575. http://dx.doi.org/10.1128/AAC.00853-06. (Pubitemid 46185274)
20. Raymond S, Delobel P, Mavigner M, Cazabat M, Souyris C, Encinas S, Bruel P, Sandres-Sauné K, Marchou B, Massip P, Izopet J. 2010. Development and performance of a new recombinant virus phenotypic entry assay to determine HIV-1 coreceptor usage. J. Clin. Virol. 47:126-130. http://dx.doi.org/10.1016/j.jcv. 2009.11.018.
21. Holland AU, Munk C, Lucero GR, Nguyen LD, Landau NR. 2004. Alpha-complementation assay for HIV envelope glycoprotein-mediated fusion. Virology 319:343-352. http://dx.doi.org/10.1016/j.virol.2003.11.012. (Pubitemid 38251274)
22. Grund S, Klein A, Adams O. 2010. Expression plasmids are only useful for the investigation of co-receptor tropism and fusion capacity of short HIV-1 envelope domains. J. Virol. Methods 166:106-109. http://dx.doi.org/10.1016/j. jviromet.2010.03.015.
23. Weber J, Vazquez AC, Winner D, Gibson RM, Rhea AM, Rose JD, Wylie D, Henry K, Wright A, King K, Archer J, Poveda E, Soriano V, Robertson DL, Olivo PD, Arts EJ, Quiñones-Mateu ME. 2013. Sensitive cell-based assay for determination of human immunodeficiency virus type 1 coreceptor tropism. J. Clin. Microbiol. 51:1517-1527. http://dx.doi.org/10.1128/JCM.00092-13.
24. Swenson LC, Moores A, Low AJ, Thielen A, Dong W, Woods C, Jensen MA, Wynhoven B, Chan D, Glascock C, Harrigan PR. 2010. Improved detection of CXCR4-using HIV by V3 genotyping: application of popu-lation-based and "deep" sequencing to plasma RNA and proviral DNA. J. Acquir. Immune Defic. Syndr. 54:506-510. http://dx.doi.org/10.1097/QAI.0b013e3181d0558f.
25. Swenson LC, Däumer M, Paredes R. 2012. Next-generation sequencing to assess HIV tropism. Curr. Opin. HIV AIDS 7:478-485. http://dx.doi.org/10.1097/ COH.0b013e328356e9da.
26. Archer J, Braverman MS, Taillon BE, Desany B, James I, Harrigan PR, Lewis M, Robertson DL. 2009. Detection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with ultradeep pyrosequencing. AIDS 23:1209-1218. http://dx.doi.org/10.1097/QAD.0b013e32832b4399.
27. Sing T, Low AJ, Beerenwinkel N, Sander O, Cheung PK, Domingues FS, Büch J, Däumer M, Kaiser R, Lengauer T, Harrigan PR. 2007. Predicting HIV coreceptor usage on the basis of genetic and clinical covariates. Antivir. Ther. 12:1097-1106. (Pubitemid 350114990)
28. Jensen MA, Li FS, van 't Wout AB, Nickle DC, Shriner D, He HX, McLaughlin S, Shankarappa R, Margolick JB, Mullins JI. 2003. Improved coreceptor usage prediction and genotypic monitoring of R5- to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J. Virol. 77:13376-13388. http://dx.doi.org/10.1128/JVI.77.24.13376-13388.2003. (Pubitemid 37494331)
29. Cardozo T, Kimura T, Philpott S, Weiser B, Burger H, Zolla-Pazner S. 2007. Structural basis for coreceptor selectivity by the HIV type 1 V3 loop. AIDS Res. Hum. Retroviruses 23:415-426. http://dx.doi.org/10.1089/aid.2006.0130. (Pubitemid 46608562)
30. Rosen O, Sharon M, Quadt-Akabayov SR, Anglister J. 2006. Molecular switch for alternative conformations of the HIV-1 V3 region: implications for phenotype conversion. Proc. Natl. Acad. Sci. U. S. A. 103: 13950-13955. http://dx.doi.org/10.1073/pnas.0606312103. (Pubitemid 44452963)
31. Poveda E, Alcamí J, Paredes R, Córdoba J, Gutiérrez F, Llibre JM, Delgado R, Pulido F, Iribarren JA, García Deltoro M, Hernández Quero J, Moreno S, García F. 2010. Genotypic determination of HIV tropism - clinical and methodological recommendations to guide the therapeutic use of CCR5 antagonists. AIDS Rev. 12:135-148.
32. Gianella S, Richman DD. 2010. Minority variants of drug-resistant HIV. J. Infect. Dis. 202:657-666. http://dx.doi.org/10.1086/655397.
33. Stekler JD, Ellis GM, Carlsson J, Eilers B, Holte S, Maenza J, Stevens CE, Collier AC, Frenkel LM. 2011. Prevalence and impact of minority variant drug resistance mutations in primary HIV-1 infection. PLoS One 6:e28952. http://dx.doi.org/10.1371/journal.pone.0028952.
34. Dunn DT, Coughlin K, Cane PA. 2011. Genotypic resistance testing in routine clinical care. Curr. Opin. HIV AIDS 6:251-257. http://dx.doi.org/10. 1097/COH.0b013e32834732e8.
35. Grant PM, Zolopa AR. 2009. The use of resistance testing in the management of HIV-1-infected patients. Curr. Opin. HIV AIDS 4:474-480. http://dx.doi.org/10.1097/COH.0b013e328331c14f.
36. Swenson LC, Mo T, Dong WW, Zhong X, Woods CK, Thielen A, Jensen MA, Knapp DJ, Chapman D, Portsmouth S, Lewis M, James I, Heera J, Valdez H, Harrigan PR. 2011. Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc. Clin. Infect. Dis. 53:732-742. http://dx.doi.org/10.1093/cid/cir493.
37. Seclén E, Soriano V, González MM, Gómez S, Thielen A, Poveda E. 2011. High concordance between the position-specific scoring matrix and Geno2Pheno algorithms for genotypic interpretation of HIV-1 tropism: V3 length as the major cause of disagreement. J. Clin. Microbiol. 49:3380-3382. http://dx.doi.org/10.1128/JCM.00908-11.
38. Recordon-Pinson P, Soulié C, Flandre P, Descamps D, Lazrek M, Charpentier C, Montes B, Trabaud MA, Cottalorda J, Schneider V, Morand-Joubert L, Tamalet C, Desbois D, Macé M, Ferré V, Vabret A, Ruffault A, Pallier C, Raymond S, Izopet J, Reynes J, Marcelin AG, Masquelier B, ANRS AC11 Resistance Study Group. 2010. Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study. Antimicrob. Agents Chemother. 54:3335-3340. http://dx.doi.org/10.1128/AAC.00148-10.
39. McGovern RA, Thielen A, Mo T, Dong W, Woods CK, Chapman D, Lewis M, James I, Heera J, Valdez H, Harrigan PR. 2010. Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies. AIDS 24:2517-2525. http://dx.doi.org/10.1097/QAD. 0b013e32833e6cfb.
40. Poveda E, Seclén E, González Mdel M, García F, Chueca N, Aguilera A, Rodríguez JJ, González-Lahoz J, Soriano V. 2009. Design and validation of new genotypic tools for easy and reliable estimation of HIV tropism before using CCR5 antagonists. J. Antimicrob. Chemother. 63: 1006-1010. http://dx.doi.org/10.1093/jac/dkp063.
41. Lin NH, Kuritzkes DR. 2009. Tropism testing in the clinical management of HIV-1 infection. Curr. Opin. HIV AIDS 4:481-487. http://dx.doi.org/10.1097/COH. 0b013e328331b929.
42. Reeves JD, Coakley E, Petropoulos CJ, Whitcomb JM. 2009. An enhanced- sensitivity Trofile HIV coreceptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5: a review of analytical and clinical studies. J. Viral Entry 3:94-102.
43. Cunningham S, Ank B, Lewis D, Lu W, Wantman M, Dileanis JA, Jackson JB, Palumbo P, Krogstad P, Eshleman SH. 2001. Performance of the applied Biosystems ViroSeq human immunodeficiency virus type 1 (HIV-1) genotyping system for sequence-based analysis of HIV-1 in pediatric plasma samples. J. Clin. Microbiol. 39:1254-1257. http://dx.doi.org/10.1128/JCM.39.4.1254-1257.2001. (Pubitemid 32275416)
44. Grant RM, Kuritzkes DR, Johnson VA, Mellors JW, Sullivan JL, Swanstrom R, D'Aquila RT, Van Gorder M, Holodniy M, Lloyd RM, Jr, Reid C, Morgan GF, Winslow DL. 2003. Accuracy of the Trugene HIV-1 genotyping kit. J. Clin. Microbiol. 41:1586-1593. http://dx.doi.org/10.1128/JCM.41.4.1586-1593.2003. (Pubitemid 36428108)
45. Larder BA, Kohli A, Kellam P, Kemp SD, Kronick M, Henfrey RD. 1993. Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing. Nature 365:671-673. http://dx.doi.org/10.1038/365671a0.
46. Church JD, Jones D, Flys T, Hoover D, Marlowe N, Chen S, Shi C, Eshleman JR, Guay LA, Jackson JB, Kumwenda N, Taha TE, Eshleman SH. 2006. Sensitivity of the ViroSeq HIV-1 genotyping system for detection of the K103N resistance mutation in HIV-1 subtypes A, C, and D. J. Mol. Diagn. 8:430-432; quiz 527. http://dx.doi.org/10.2353/jmoldx.2006.050148.
47. Halvas EK, Aldrovandi GM, Balfe P, Beck IA, Boltz VF, Coffin JM, Frenkel LM, Hazelwood JD, Johnson VA, Kearney M, Kovacs A, Kuritzkes DR, Metzner KJ, Nissley DV, Nowicki M, Palmer S, Ziermann R, Zhao RY, Jennings CL, Bremer J, Brambilla D, Mellors JW. 2006. Blinded, multicenter comparison of methods to detect a drugresistant mutant of human immunodeficiency virus type 1 at low frequency. J. Clin. Microbiol. 44:2612-2614. http://dx.doi.org/10.1128/JCM. 00449-06. (Pubitemid 44092442)
48. Leitner T, Halapi E, Scarlatti G, Rossi P, Albert J, Fenyö EM, Uhlén M. 1993. Analysis of heterogeneous viral populations by direct DNA sequencing. Biotechniques 15:120-127. (Pubitemid 23202530)
49. Paredes R, Lalama CM, Ribaudo HJ, Schackman BR, Shikuma C, Giguel F, Meyer WA, III, Johnson VA, Fiscus SA, D'Aquila RT, Gulick RM, Kuritzkes DR, AIDS Clinical Trials Group (ACTG) A5095 Study Team. 2010. Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. J. Infect. Dis. 201:662-671. http://dx.doi.org/10.1086/650543.
50. Johnson JA, Li JF, Wei X, Lipscomb J, Irlbeck D, Craig C, Smith A, Bennett DE, Monsour M, Sandstrom P, Lanier ER, Heneine W. 2008. Minority HIV-1drug resistance mutations are present in antiretroviral treatment- naive populations and associate with reduced treatment efficacy. PLoS Med. 5:e158. http://dx.doi.org/10.1371/journal.pmed.0050158.
51. Simen BB, Simons JF, Hullsiek KH, Novak RM, Macarthur RD, Baxter JD, Huang C, Lubeski C, Turenchalk GS, Braverman MS, Desany B, Rothberg JM, Egholm M, Kozal MJ, Terry Beirn Community Programs for Clinical Research on AIDS. 2009. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. J. Infect. Dis. 199:693-701. http://dx.doi.org/10.1086/596736.
52. Metzner KJ, Giulieri SG, Knoepfel SA, Rauch P, Burgisser P, Yerly S, Gunthard HF, Cavassini M. 2009. Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients. Clin. Infect. Dis. 48:239-247. http://dx.doi.org/10.1086/595703.
53. Kuritzkes DR, Lalama CM, Ribaudo HJ, Marcial M, Meyer WA, III, Shikuma C, Johnson VA, Fiscus SA, D'Aquila RT, Schackman BR, Acosta EP, Gulick RM. 2008. Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. J. Infect. Dis. 197:867-870. http://dx.doi.org/10.1086/ 528802. (Pubitemid 351417010)
54. Halvas EK, Wiegand A, Boltz VF, Kearney M, Nissley D, Wantman M, Hammer SM, Palmer S, Vaida F, Coffin JM, Mellors JW. 2010. Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment-experienced patients. J. Infect. Dis. 201:672-680. http://dx.doi.org/10.1086/650542.
55. Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Kozal MJ, Hullsiek KH, Miller MD, Bangsberg DR, Kuritzkes DR. 2012. Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure. AIDS 26:185-192. http://dx.doi.org/10.1097/ QAD.0b013e32834e9d7d.
56. Fisher R, van Zyl GU, Travers SA, Kosakovsky Pond SL, Engelbrech S, Murrell B, Scheffler K, Smith D. 2012. Deep sequencing reveals minor protease resistance mutations in patients failing a protease inhibitor regimen. J. Virol. 86:6231-6237. http://dx.doi.org/10.1128/JVI.06541-11.
57. Li JZ, Kuritzkes DR. 2013. Clinical implications of HIV-1 minority variants. Clin. Infect. Dis. 56:1667-1674. http://dx.doi.org/10.1093/cid/cit125.
58. Palmer S, Boltz V, Maldarelli F, Kearney M, Halvas EK, Rock D, Falloon J, Davey RT, Jr, Dewar RL, Metcalf JA, Mellors JW, Coffin JM. 2006. Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy. AIDS 20:701-710. http://dx.doi.org/10.1097/01.aids.0000216370.69066.7f. (Pubitemid 43884297)
59. Lalonde MS, Troyer RM, Syed AR, Bulime S, Demers K, Bajunirwe F, Arts EJ. 2007. Sensitive oligonucleotide ligation assay for low-level detection of nevirapine resistance mutations in human immunodeficiency virus type 1 quasispecies. J. Clin. Microbiol. 45:2604-2615. http://dx.doi.org/10.1128/JCM. 00431-07. (Pubitemid 47295494)
60. Avidor B, Girshengorn S, Matus N, Talio H, Achsanov S, Zeldis I, Fratty IS, Katchman E, Brosh-Nissimov T, Hassin D, Alon D, Bentwich Z, Yust I, Amit S, Forer R, Vulih Shultsman I, Turner D. 2013. Evaluation of a benchtop HIV ultradeep pyrosequencing drug resistance assay in the clinical laboratory. J. Clin. Microbiol. 51:880-886. http://dx.doi.org/10.1128/JCM.02652-12.
61. Chang MW, Oliveira G, Yuan J, Okulicz JF, Levy S, Torbett BE. 2013. Rapid deep sequencing of patient-derived HIV with ion semiconductor technology. J. Virol. Methods 189:232-234. http://dx.doi.org/10.1016/j.jviromet.2013.01.019.
62. Dudley DM, Chin EN, Bimber BN, Sanabani SS, Tarosso LF, Costa PR, Sauer MM, Kallas EG, O'Connor DH. 2012. Low-cost ultra-wide genotyping using Roche/454 pyrosequencing for surveillance of HIV drug resistance. PLoS One 7:e36494. http://dx.doi.org/10.1371/journal.pone.0036494.
63. Swenson LC, Mo T, Dong WW, Zhong X, Woods CK, Jensen MA, Thielen A, Chapman D, Lewis M, James I, Heera J, Valdez H, Harrigan PR. 2011. Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients. J. Infect. Dis. 203:237-245. http://dx.doi.org/10.1093/infdis/jiq030.
64. Saliou A, Delobel P, Dubois M, Nicot F, Raymond S, Calvez V, Masquelier B, Izopet J, ANRS AC11 Resistance Study Group. 2011. Concordance between two phenotypic assays and ultradeep pyrosequencing for determining HIV-1 tropism. Antimicrob. Agents Chemother. 55:2831-2836. http://dx.doi.org/10.1128/AAC.00091- 11.
65. Kagan RM, Johnson EP, Siaw MF, Van Baelen B, Ogden R, Platt JL, Pesano RL, Lefebvre E. 2014. Comparison of genotypic and phenotypic HIV type 1 tropism assay: results from the screening samples of cenicriviroc study 202, a randomized phase II trial in treatment-naive subjects. AIDS Res. Hum. Retroviruses 30:151-159. http://dx.doi.org/10.1089/aid.2013.0123.
66. Kagan RM, Johnson EP, Siaw M, Biswas P, Chapman DS, Su Z, Platt JL, Pesano RL. 2012. A genotypic test for HIV-1 tropism combining Sanger sequencing with ultradeep sequencing predicts virologic response in treatment-experienced patients. PLoS One 7:e46334. http://dx.doi.org /10.1371/journal.pone.0046334.
67. Archer J, Weber J, Henry K, Winner D, Gibson R, Lee L, Paxinos E, Arts EJ, Robertson DL, Mimms L, Quiñones-Mateu ME. 2012. Use of four next-generation sequencing platforms to determine HIV-1 coreceptor tropism. PLoS One 7:e49602. http://dx.doi.org/10.1371/journal.pone.0049602.
68. Weber J, Rose JD, Vazquez AC, Winner D, Margot N, McColl DJ, Miller MD, Quiñones-Mateu ME. 2013. Resistance mutations outside the integrase coding region have an effect on human immunodeficiency virus replicative fitness but do not affect its susceptibility to integrase strand transfer inhibitors. PLoS One 8:e65631. http://dx.doi.org/10.1371/journal.pone.0065631.
69. Weber J, Quiñones-Mateu ME. 2007. Novel anti-HIV-1 screening system based on intact recombinant viruses expressing synthetic firefly and Renilla luminescent proteins. Antivir. Ther. 12:S155.
70. Moreno S, Clotet B, Sarria C, Ortega E, Leal M, Rodríguez-Arrondo F, Sánchez-de la Rosa R, Allegro Study Group. 2009. Prevalence of CCR5- tropic HIV-1 among treatment-experienced individuals in Spain. HIV Clin. Trials 10:394-402. http://dx.doi.org/10.1310/hct1006-394.
71. Gonzalez-Serna A, Romero-Sánchez MC, Ferrando-Martinez S, Genebat M, Vidal F, Muñoz-Fernández MA, Abad MA, Leal M, Ruiz-Mateos E. 2012. HIV-1 tropism evolution after short-term maraviroc monotherapy in HIV-1-infected patients. Antimicrob. Agents Chemother. 56:3981-3983. http://dx.doi.org/10.1128/AAC.00507-12.
72. Romero-Sánchez MC, Machmach K, Gonzalez-Serna A, Genebat M, Pulido I, García-García M, Alvarez-Ríos AI, Ferrando-Martinez S, Ruiz-Mateos E, Leal M. 2012. Effect of maraviroc on HIV disease progression-related biomarkers. Antimicrob. Agents Chemother. 56:5858-5864. http://dx.doi.org/10.1128/AAC.01406-12.
73. Gonzalez-Serna A, Leal M, Genebat M, Abad MA, Garcia-Perganeda A, Ferrando-Martinez S, Ruiz-Mateos E. 2010. TROCAI (tropism coreceptor assay information): a new phenotypic tropism test and its correlation with Trofile enhanced sensitivity and genotypic approaches. J. Clin. Microbiol. 48:4453-4458. http://dx.doi.org/10.1128/JCM.00953-10.
74. Quiñones-Mateu ME, Domingo E. 1999. Nucleotide diversity in three different genomic regions of Venezuelan HIV type 1 isolates: a subtyping update. AIDS Res. Hum. Retroviruses 15:73-79.
75. Archer J, Rambaut A, Taillon BE, Harrigan PR, Lewis M, Robertson DL. 2010. The evolutionary analysis of emerging low frequency HIV-1 CXCR4 using variants through time-an ultra-deep approach. PLoS Comput. Biol. 6:e1001022. http://dx.doi.org/10.1371/journal.pcbi.1001022.
76. Archer J, Baillie G, Watson SJ, Kellam P, Rambaut A, Robertson DL. 2012. Analysis of high-depth sequence data for studying viral diversity: a comparison of next generation sequencing platforms using Segminator II. BMC Bioinformatics 13:47. http://dx.doi.org/10.1186/1471-2105-13-47.
77. Johnson VA, Calvez V, Gunthard HF, Paredes R, Pillay D, Shafer RW, Wensing AM, Richman DD. 2013. Update of the drug resistance mutations in HIV-1: March 2013. Top. Antivir. Med. 21:6-14.
78. Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, Valentin F, Wallace IM, Wilm A, Lopez R, Thompson JD, Gibson TJ, Higgins DG. 2007. Clustal W and Clustal X version 2.0. Bioinformatics 23:2947-2948. http://dx.doi.org/10.1093/bioinformatics/btm404. (Pubitemid 350162903)
79. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. 2011. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol. Biol. Evol. 28:2731-2739. http://dx.doi.org/10.1093/molbev/msr121.
80. Harrigan PR. 2009. MOTIVATE tropism study group. Optimization of clinical cutoffs for determining HIV co-receptor use by population and "deep" sequencing methods. Poster 297. Infectious Diseases Society of America, Philadelphia, PA, 30 October 2009.
81. Bunnik EM, Swenson LC, Edo-Matas D, Huang W, Dong W, Frantzell A, Petropoulos CJ, Coakley E, Schuitemaker H, Harrigan PR, van 't Wout AB. 2011. Detection of inferred CCR5- and CXCR4-using HIV-1 variants and evolutionary intermediates using ultra-deep pyrosequencing. PLoS Pathog. 7:e1002106. http://dx.doi.org/10.1371/journal.ppat.1002106.
82. Lobritz MA, Marozsan AJ, Troyer RM, Arts EJ. 2007. Natural variation in the V3 crown of human immunodeficiency virus type 1 affects replicative fitness and entry inhibitor sensitivity. J. Virol. 81:8258-8269. http://dx.doi.org/10. 1128/JVI.02739-06. (Pubitemid 47101511)
83. Robinson BF, Bakeman R. 1998. ComKappa: a Windows 95 program for calculating kappa and related statistics. Behav. Res. Methods Instrum. Comput. 30:731-732. http://dx.doi.org/10.3758/BF03209495.
84. Shao W, Boltz VF, Spindler JE, Kearney MF, Maldarelli F, Mellors JW, Stewart C, Volfovsky N, Levitsky A, Stephens RM, Coffin JM. 2013. Analysis of 454 sequencing error rate, error sources, and artifact recombination for detection of low-frequency drug resistance mutations in HIV-1 DNA. Retrovirology 10:18. http://dx.doi.org/10.1186/1742-4690-10-18.
85. Wang C, Mitsuya Y, Gharizadeh B, Ronaghi M, Shafer RW. 2007. Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance. Genome Res. 17:1195-1201. http://dx.doi.org/10.1101/ gr.6468307. (Pubitemid 47204863)
86. Sato T, Matsuyama J, Kumagai T, Mayanagi G, Yamaura M, Washio J, Takahashi N. 2003. Nested PCR for detection of mutans streptococci in dental plaque. Lett. Appl. Microbiol. 37:66-69. http://dx.doi.org/10.1046/j.1472-765X. 2003.01359.x. (Pubitemid 36783083)
87. Garrido C, Soriano V, Geretti AM, Zahonero N, Garcia S, Booth C, Gutierrez F, Viciana I, de Mendoza C. 2011. Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients-impact of HIV subtypes and prior raltegravir experience. Antiviral Res. 90:164-167. http://dx.doi.org/10. 1016/j.antiviral.2011.03.178.
88. Marx JL. 1989. Drug-resistant strains of AIDS virus found. Science 243: 1551-1552. http://dx.doi.org/10.1126/science.2928791.
89. MacArthur RD. 2009. Understanding HIV phenotypic resistance testing: usefulness in managing treatment-experienced patients. AIDS Rev. 11:223-230.
90. Bentley DR, Balasubramanian S, Swerdlow HP, Smith GP, Milton J, Brown CG, Hall KP, Evers DJ, Barnes CL, Bignell HR, Boutell JM, Bryant J, Carter RJ, Keira Cheetham R, Cox AJ, Ellis DJ, Flatbush MR, Gormley NA, Humphray SJ, Irving LJ, Karbelashvili MS, Kirk SM, Li H, Liu X, Maisinger KS, Murray LJ, Obradovic B, Ost T, Parkinson ML, Pratt MR, Rasolonjatovo IM, Reed MT, Rigatti R, Rodighiero C, Ross MT, Sabot A, Sankar SV, Scally A, Schroth GP, Smith ME, Smith VP, Spiridou A, Torrance PE, Tzonev SS, Vermaas EH, Walter K, Wu X, Zhang L, Alam MD, Anastasi C, et al. 2008. Accurate whole human genome sequencing using reversible terminator chemistry. Nature 456: 53-59. http://dx.doi.org/10.1038/ nature07517.
91. Scally A, Dutheil JY, Hillier LW, Jordan GE, Goodhead I, Herrero J, Hobolth A, Lappalainen T, Mailund T, Marques-Bonet T, McCarthy S, Montgomery SH, Schwalie PC, Tang YA, Ward MC, Xue Y, Yngvadottir B, Alkan C, Andersen LN, Ayub Q, Ball EV, Beal K, Bradley BJ, Chen Y, Clee CM, Fitzgerald S, Graves TA, Gu Y, Heath P, Heger A, Karakoc E, Kolb-Kokocinski A, Laird GK, Lunter G, Meader S, Mort M, Mullikin JC, Munch K, O'Connor TD, Phillips AD, Prado-Martinez J, Rogers AS, Sajjadian S, Schmidt D, Shaw K, Simpson JT, Stenson PD, Turner DJ, Vigilant L, Vilella AJ, et al. 2012. Insights into hominid evolution from the gorilla genome sequence. Nature 483:169-175. http://dx.doi.org/10.1038/nature10842.
92. Chatterjee R, Hoffman M, Cliften P, Seshan S, Liapis H, Jain S. 2013. Targeted exome sequencing integrated with clinicopathological information reveals novel and rare mutations in atypical, suspected and unknown cases of Alport syndrome or proteinuria. PLoS One 8:e76360. http://dx.doi.org/10.1371/ journal.pone.0076360.
93. Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, Arthur CD, White JM, Chen YS, Shea LK, Hundal J, Wendl MC, Demeter R, Wylie T, Allison JP, Smyth MJ, Old LJ, Mardis ER, Schreiber RD. 2012. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482:400-404. http://dx.doi.org/10.1038/nature10755.
94. Roychowdhury S, Iyer MK, Robinson DR, Lonigro RJ, Wu YM, Cao X, Kalyana-Sundaram S, Sam L, Balbin OA, Quist MJ, Barrette T, Everett J, Siddiqui J, Kunju LP, Navone N, Araujo JC, Troncoso P, Logothetis CJ, Innis JW, Smith DC, Lao CD, Kim SY, Roberts JS, Gruber SB, Pienta KJ, Talpaz M, Chinnaiyan AM. 2011. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci. Transl. Med. 3:111ra121. http://dx.doi.org/10.1126/ scitranslmed.3003161.
95. Howden BP, McEvoy CR, Allen DL, Chua K, Gao W, Harrison PF, Bell J, Coombs G, Bennett-Wood V, Porter JL, Robins-Browne R, Davies JK, Seemann T, Stinear TP. 2011. Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR. PLoS Pathog. 7:e1002359. http://dx.doi.org/10.1371/journal.ppat.1002359.
96. Chin CS, Sorenson J, Harris JB, Robins WP, Charles RC, Jean-Charles RR, Bullard J, Webster DR, Kasarskis A, Peluso P, Paxinos EE, Yamaichi Y, Calderwood SB, Mekalanos JJ, Schadt EE, Waldor MK. 2011. The origin of the Haitian cholera outbreak strain. N. Engl. J. Med. 364:33-42. http://dx.doi.org/10.1056/ NEJMoa1012928.
97. Umemura M, Koyama Y, Takeda I, Hagiwara H, Ikegami T, Koike H, Machida M. 2013. Fine de novo sequencing of a fungal genome using only SOLiD short read data: verification on Aspergillus oryzae RIB40. PLoS One 8:e63673. http://dx.doi.org/10.1371/journal.pone.0063673.
98. Wu X, Zhou T, Zhu J, Zhang B, Georgiev I, Wang C, Chen X, Longo NS, Louder M, McKee K, O'Dell S, Perfetto S, Schmidt SD, Shi W, Wu L, Yang Y, Yang ZY, Yang Z, Zhang Z, Bonsignori M, Crump JA, Kapiga SH, Sam NE, Haynes BF, Simek M, Burton DR, Koff WC, Doria-Rose NA, Connors M, NISC Comparative Sequencing Program, Mullikin JC, Nabel GJ, Roederer M, Shapiro L, Kwong PD, Mascola JR. 2011. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333:1593-1602. http://dx.doi.org/10.1126/science. 1207532.
99. Quan PL, Firth C, Conte JM, Williams SH, Zambrana-Torrelio CM, Anthony SJ, Ellison JA, Gilbert AT, Kuzmin IV, Niezgoda M, Osinubi MO, Recuenco S, Markotter W, Breiman RF, Kalemba L, Malekani J, Lindblade KA, Rostal MK, Ojeda-Flores R, Suzan G, Davis LB, Blau DM, Ogunkoya AB, Alvarez Castillo DA, Moran D, Ngam S, Akaibe D, Agwanda B, Briese T, Epstein JH, Daszak P, Rupprecht CE, Holmes EC, Lipkin WI. 2013. Bats are a major natural reservoir for hepaciviruses and pegiviruses. Proc. Natl. Acad. Sci. U. S. A. 110:8194-8199. http://dx.doi.org/10.1073/pnas.1303037110.
100. Henn MR, Boutwell CL, Charlebois P, Lennon NJ, Power KA, Macalalad AR, Berlin AM, Malboeuf CM, Ryan EM, Gnerre S, Zody MC, Erlich RL, Green LM, Berical A, Wang Y, Casali M, Streeck H, Bloom AK, Dudek T, Tully D, Newman R, Axten KL, Gladden AD, Battis L, Kemper M, Zeng Q, Shea TP, Gujja S, Zedlack C, Gasser O, Brander C, Hess C, Günthard HF, Brumme ZL, Brumme CJ, Bazner S, Rychert J, Tinsley JP, Mayer KH, Rosenberg E, Pereyra F, Levin JZ, Young SK, Jessen H, Altfeld M, Birren BW, Walker BD, Allen TM. 2012. Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants upon immune recognition during acute infection. PLoS Pathog. 8:e1002529. http://dx.doi.org/10.1371/journal. ppat.1002529.
101. Vandenbroucke I, Van Marck H, Mostmans W, Van Eygen V, Rondelez E, Thys K, Van Baelen K, Fransen K, Vaira D, Kabeya K, De Wit S, Florence E, Moutschen M, Vandekerckhove L, Verhofstede C, Stuyver LJ. 2010. HIV-1 V3 envelope deep sequencing for clinical plasma specimens failing in phenotypic tropism assays. AIDS Res. Ther. 7:4. http://dx.doi.org/10.1186/1742-6405-7-4.
102. Raymond S, Saliou A, Nicot F, Delobel P, Dubois M, Cazabat M, Sandres-Sauné K, Marchou B, Massip P, Izopet J. 2011. Frequency of CXCR4-using viruses in primary HIV-1 infections using ultra-deep pyrosequencing. AIDS 25:1668-1670. http://dx.doi.org/10.1097/QAD.0b013e3283498305.
103. Abbate I, Vlassi C, Rozera G, Bruselles A, Bartolini B, Giombini E, Corpolongo A, D'Offizi G, Narciso P, Desideri A, Ippolito G, Capobianchi MR. 2011. Detection of quasispecies variants predicted to use CXCR4 by ultra-deep pyrosequencing during early HIV infection. AIDS 25:611-617. http://dx.doi.org/ 10.1097/QAD.0b013e328343489e.
104. Lee GQ, Harrigan PR, Dong W, Poon AF, Heera J, Demarest J, Rinehart A, Chapman D, Valdez H, Portsmouth S. 2013. Comparison of population and 454 "deep" sequence analysis for HIV type 1 tropism versus the original Trofile assay in non-B subtypes. AIDS Res. Hum. Retroviruses 29:979-984. http://dx.doi.org/10.1089/aid.2012.0338.
105. Messiaen P, Verhofstede C, Vandenbroucke I, Dinakis S, Van Eygen V, Thys K, Winters B, Aerssens J, Vogelaers D, Stuyver LJ, Vandekerckhove L. 2012. Ultra-deep sequencing of HIV-1 reverse transcriptase before start of an NNRTI-based regimen in treatment-naive patients. Virology 426:7-11. http://dx.doi.org/10.1016/j.virol.2012.01.002.
106. Armenia D, Vandenbroucke I, Fabeni L, Van Marck H, Cento V, D'Arrigo R, Van Wesenbeeck L, Scopelliti F, Micheli V, Bruzzone B, Lo Caputo S, Aerssens J, Rizzardini G, Tozzi V, Narciso P, Antinori A, Stuyver L, Perno CF, Ceccherini-Silberstein F. 2012. Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing. J. Infect. Dis. 205:557-567. http://dx.doi.org/ 10.1093/infdis/jir821.
107. Mukherjee R, Jensen ST, Male F, Bittinger K, Hodinka RL, Miller MD, Bushman FD. 2011. Switching between raltegravir resistance pathways analyzed by deep sequencing. AIDS 25:1951-1959. http://dx.doi.org/10.1097/QAD. 0b013e32834b34de.
108. Liu J, Miller MD, Danovich RM, Vandergrift N, Cai F, Hicks CB, Hazuda DJ, Gao F. 2011. Analysis of low-frequency mutations associated with drug resistance to raltegravir before antiretroviral treatment. Antimicrob. Agents Chemother. 55:1114-1119. http://dx.doi.org/10.1128/AAC.01492-10.
109. Gall A, Ferns B, Morris C, Watson S, Cotten M, Robinson M, Berry N, Pillay D, Kellam P. 2012. Universal amplification, next-generation sequencing, and assembly of HIV-1 genomes. J. Clin. Microbiol. 50:3838-3844. http://dx.doi.org/10.1128/JCM.01516-12.
110. Huse SM, Huber JA, Morrison HG, Sogin ML, Welch DM. 2007. Accuracy and quality of massively parallel DNA pyrosequencing. Genome Biol. 8:R143. http://dx.doi.org/10.1186/gb-2007-8-7-r143.
111. Loman NJ, Misra RV, Dallman TJ, Constantinidou C, Gharbia SE, Wain J, Pallen MJ. 2012. Performance comparison of benchtop high-throughput sequencing platforms. Nat. Biotechnol. 30:434-439. http://dx.doi.org/10.1038/nbt.2198.
112. Brodin J, Mild M, Hedskog C, Sherwood E, Leitner T, Andersson B, Albert J. 2013. PCR-induced transitions are the major source of error in cleaned ultra-deep pyrosequencing data. PLoS One 8:e70388. http://dx.doi.org/10.1371/ journal.pone.0070388.
113. Rozera G, Abbate I, Bruselles A, Vlassi C, D'Offizi G, Narciso P, Chillemi G, Prosperi M, Ippolito G, Capobianchi MR. 2009. Massively parallel pyrosequencing highlights minority variants in the HIV-1 env quasispecies deriving from lymphomonocyte sub-populations. Retrovirology 6:15. http://dx.doi.org/10.1186/1742-4690-6-15.
114. Zagordi O, Däumer M, Beisel C, Beerenwinkel N. 2012. Read length versus depth of coverage for viral quasispecies reconstruction. PLoS One 7:e47046. http://dx.doi.org/10.1371/journal.pone.0047046.
115. Willerth SM, Pedro HA, Pachter L, Humeau LM, Arkin AP, Schaffer DV. 2010. Development of a low bias method for characterizing viral populations using next generation sequencing technology. PLoS One 5:e13564. http://dx.doi.org/10. 1371/journal.pone.0013564.
116. Church JD, Huang W, Parkin N, Marlowe N, Guay LA, Omer SB, Musoke P, Jackson JB, Eshleman SH. 2009. Comparison of laboratory methods for analysis of non-nucleoside reverse transcriptase inhibitor resistance in Ugandan infants. AIDS Res. Hum. Retroviruses 25:657-663. http://dx.doi.org/10.1089/aid.2008.0235.
117. Gallego O, Martin-Carbonero L, Aguero J, de Mendoza C, Soriano V. 2004. Correlation between rules-based interpretation and virtual phenotype interpretation of HIV-1 genotypes for predicting drug resistance in HIV-infected individuals. J. Virol. Methods 121:115-118. (Pubitemid 39180033)
118. Dunne AL, Mitchell FM, Coberly SK, Hellmann NS, Hoy J, Mijch A, Petropoulos CJ, Mills J, Crowe SM. 2001. Comparison of genotyping and phenotyping methods for determining susceptibility of HIV-1 to antiretroviral drugs. AIDS 15:1471-1475. http://dx.doi.org/10.1097/00002030-200108170-00003. (Pubitemid 32744593)
119. Qari SH, Respess R, Weinstock H, Beltrami EM, Hertogs K, Larder BA, Petropoulos CJ, Hellmann N, Heneine W. 2002. Comparative analysis of two commercial phenotypic assays for drug susceptibility testing of human immunodeficiency virus type 1. J. Clin. Microbiol. 40:31-35. http://dx.doi.org/10.1128/JCM.40.1.31-35.2002. (Pubitemid 34027597)
120. Wang K, Samudrala R, Mittler JE. 2004. Antivirogram or PhenoSense: a comparison of their reproducibility and an analysis of their correlation. Antivir. Ther. 9:703-712. (Pubitemid 39434333)
121. Skrabal K, Low AJ, Dong W, Sing T, Cheung PK, Mammano F, Harrigan PR. 2007. Determining human immunodeficiency virus coreceptor use in a clinical setting: degree of correlation between two phenotypic assays and a bioinformatic model. J. Clin. Microbiol. 45:279-284. http://dx.doi.org/10.1128/jcm.01118-06.
122. de Mendoza C, Van Baelen K, Poveda E, Rondelez E, Zahonero N, Stuyver L, Garrido C, Villacian J, Soriano V. 2008. Performance of a population-based HIV-1 tropism phenotypic assay and correlation with V3 genotypic prediction tools in recent HIV-1 seroconverters. J. Acquir. Immune Defic. Syndr. 48: 241-244. http://dx.doi.org/10.1097/QAI.0b013e3181734f03.
123. Raymond S, Delobel P, Mavigner M, Cazabat M, Souyris C, Sandres-Sauné K, Cuzin L, Marchou B, Massip P, Izopet J. 2008. Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism. AIDS 22:F11-F16. http://dx.doi.org/10.1097/QAD. 0b013e32830ebcd4.
124. Trabaud MA, Icard V, Scholtes C, Perpoint T, Koffi J, Cotte L, Makhloufi D, Tardy JC, André P. 2012. Discordance in HIV-1 coreceptor use prediction by different genotypic algorithms and phenotype assay: intermediate profile in relation to concordant predictions. J. Med. Virol. 84:402-413. http://dx.doi.org/10.1002/jmv.23209.
125. Pou C, Codoñer FM, Thielen A, Bellido R, Pérez- Álvarez S, Cabrera C, Dalmau J, Curriu M, Lie Y, Noguera-Julian M, Puig J, Martínez-Picado J, Blanco J, Coakley E, Däumer M, Clotet B, Paredes R. 2013. HIV-1 tropism testing in subjects achieving undetectable HIV-1 RNA: diagnostic accuracy, viral evolution and compartmentalization. PLoS One 8:e67085. http://dx.doi.org/10.1371/journal.pone.0067085.
126. Gonzalez-Serna A, McGovern RA, Harrigan PR, Vidal F, Poon AF, Ferrando-Martinez S, Abad MA, Genebat M, Leal M, Ruiz-Mateos E. 2012. Correlation of the virological response to short-term maraviroc monotherapy with standard and deep-sequencing-based genotypic tropism prediction methods. Antimicrob. Agents Chemother. 56:1202-1207. http://dx.doi.org/10.1128/AAC.05857- 11.
127. Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Metzner KJ, Kozal MJ, Hullsiek KH, Balduin M, Jakobsen MR, Geretti AM, Thiebaut R, Ostergaard L, Masquelier B, Johnson JA, Miller MD, Kuritzkes DR. 2011. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA 305:1327-1335. http://dx.doi.org/10.1001/jama.2011.375.
128. Li JZ, Paredes R, Ribaudo HJ, Kozal MJ, Svarovskaia ES, Johnson JA, Geretti AM, Metzner KJ, Jakobsen MR, Hullsiek KH, Ostergaard L, Miller MD, Kuritzkes DR. 2013. Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure. J. Infect. Dis. 207:893-897. http://dx.doi.org/10.1093/infdis/jis925.
129. Codoñer FM, Pou C, Thielen A, García F, Delgado R, Dalmau D, Álvarez-Tejado M, Ruiz L, Clotet B, Paredes R. 2011. Added value of deep sequencing relative to population sequencing in heavily pre-treated HIV-1-infected subjects. PLoS One 6:e19461. http://dx.doi.org/10.1371/journal. pone.0019461.